一项紫杉醇 ± tovecimig 治疗既往经治晚期胆道癌患者的随机试验
#ESMO26 #ESMOAmbassadors
👉 ORR：18% vs 5.3%
👉 mPFS：4.7 vs 2.6 个月
👉 mOS：8.9 vs 9.4 个月
🧐该药物具有活性，但在二线治疗中未显示 OS 获益，可探索用于一线治疗
@myESMO @ASCO
92 浏览 · 4 赞 · 4 转发 · 0 回复
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for taxane-pretreated patients with advanced or metastatic gastroesophageal adenocarcinoma–Final results of the phase III IKFs602/AIO RAMIRIS Study
https://esmocongress.esmo.orgDESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (
https://esmocongress.esmo.orgDurvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): Interim overall survival (OS) and safety from the randomised phase 3 DUO-E/GOG-3041/ENGOT-EN10 stud
https://esmocongress.esmo.org来源：Arndt Vogel · x.com